Unknown

Dataset Information

0

In vitro evaluation of a self-emulsifying drug delivery system (SEDDS) for nasal administration of dimenhydrinate.

ABSTRACT: The objective of the study was the development and in vitro characterization of a self-emulsifying drug delivery system (SEDDS) for the nasal application of dimenhydrinate. Final composition of SEDDS was established based on drug solubility and stability studies. Dimenhydrinate was loaded into the SEDDS pre-concentrates to 7.5% (m/v). The droplet size of the final SEDDS formulations was in a range between 60 and 220 nm. Permeability, as well as tissue toxicity, of the formulations was investigated using bovine nasal mucosa. Enhancement in permeation up to 2.8-fold compared to pure dimenhydrinate was confirmed. Furthermore, toxicity studies did not reveal any serious tissue damages related to the SEDDS. Additionally, irritation potential of SEDDS was evaluated in ciliary beat frequency measurements. Incorporation of dimenhydrinate into SEDDS might therefore be considered as a promising approach within the field of nasal delivery of antiemetics by utilizing permeation enhancement strategy.

SUBMITTER: Leichner C 

PROVIDER: S-EPMC6731199 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

In vitro evaluation of a self-emulsifying drug delivery system (SEDDS) for nasal administration of dimenhydrinate.

Leichner Christina C   Baus Randi Angela RA   Jelkmann Max M   Plautz Melanie M   Barthelmes Jan J   Dünnhaupt Sarah S   Bernkop-Schnürch Andreas A  

Drug delivery and translational research 20191001 5

The objective of the study was the development and in vitro characterization of a self-emulsifying drug delivery system (SEDDS) for the nasal application of dimenhydrinate. Final composition of SEDDS was established based on drug solubility and stability studies. Dimenhydrinate was loaded into the SEDDS pre-concentrates to 7.5% (m/v). The droplet size of the final SEDDS formulations was in a range between 60 and 220 nm. Permeability, as well as tissue toxicity, of the formulations was investigat  ...[more]

Similar Datasets

Unknown Oligonucleotide Delivery across the Caco-2 Monolayer: The Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS).
| S-EPMC8066367 | biostudies-literature
Unknown Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: in vivo and in vitro studies.
| S-EPMC3691427 | biostudies-other
Unknown A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects.
| S-EPMC6720748 | biostudies-literature
Unknown Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb<sup>®</sup> Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS).
| S-EPMC9104399 | biostudies-literature
Unknown Development of a Self-Emulsifying Drug Delivery System for Optimized Topical Delivery of Clofazimine.
| S-EPMC7356627 | biostudies-literature
Unknown Preparation and Characterization of Self Nano-Emulsifying Drug Delivery System Loaded with Citraland Its Antiproliferative Effect on Colorectal Cells In Vitro.
| S-EPMC6669672 | biostudies-literature
Unknown In Vitro Evaluation of Self-Nano-Emulsifying Drug Delivery Systems (SNEDDS) Containing Room Temperature Ionic Liquids (RTILs) for the Oral Delivery of Amphotericin B.
| S-EPMC7463809 | biostudies-literature
Unknown Formulation and In Vivo Evaluation of a Solid Self-Emulsifying Drug Delivery System Using Oily Liquid Tocotrienols as Model Active Substance.
| S-EPMC8621674 | biostudies-literature
Unknown Novel Self-Nano-Emulsifying Drug Delivery Systems Containing Astaxanthin for Topical Skin Delivery.
| S-EPMC8147608 | biostudies-literature
Unknown Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity.
| S-EPMC4886259 | biostudies-literature